Rhinorrhea Reduction Using BepreveTm Ophthalmic Solution 1.5% in a Clinical Model of Allergic Conjunctivitis: An Analysis of Pooled Data From Two Phase 3 Conjunctival Allergen Challenge (CAC) Clinical Trials

被引：0
|
作者：
Gow, J. A. [1 ]
Williams, J. I. [2 ]
Gomes, P. J. [3 ]
Abelson, M. B. [4 ]
McNamara, T. R. [5 ]
机构：
[1] ISTA Pharmaceut Inc, Irvine, CA USA
[2] ISTA Pharmaceut Inc, Clin Res, Allergy, Irvine, CA USA
[3] ORA, Clin Res, Allergy, Andover, MA USA
[4] ORA, Andover, MA USA
[5] ISTA Pharmaceut Inc, Clin Res & Med Affairs, Irvine, CA USA
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2010年 / 51卷 / 13期
关键词：
conjunctivitis; drug toxicity/drug effects; clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials;
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
1915
引用
收藏
页数：2
相关论文
共 50 条
  • [11] POOLED ANALYSIS OF 2 CONFIRMATORY TRIALS EVALUATING THE EFFICACY AND SAFETY OF OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION 0.77% USING A CONJUNCTIVAL ALLERGEN CHALLENGE MODEL
    McLaurin, Eugene B.
    Narvekar, Abhijit
    Adewale, Adeniyi
    Gomes, Paul J.
    Torkildsen, Gail
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [12] Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trials
    Fahmy, Ahmad M.
    Harthan, Jennifer S.
    Evans, David G.
    Greiner, Jack V.
    Tauber, Joseph
    Sheppard, John D.
    Krosser, Sonja
    Vittitow, Jason L.
    FRONTIERS IN OPHTHALMOLOGY, 2024, 4
  • [13] Efficacy and Safety Of a New Olopatadine Hydrochloride, 0.77% Ophthalmic Formulation In Patients With Allergic Conjunctivitis Using The Conjunctival Allergen Challenge (CAC) Model (NCT01479374)
    Torkildsen, Gail
    Macejko, Thomas
    Narvekar, Abhijit
    Bergmann, Mark
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB277 - AB277
  • [14] Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model
    McLaurin, Eugene
    Narvekar, Abhijit
    Gomes, Paul
    Adewale, Adeniyi
    Torkildsen, Gail
    CORNEA, 2015, 34 (10) : 1245 - 1251
  • [15] Phase 3 Study of Efficacy and Safety of Once-daily Olopatadine Hydrochloride, 0.77% Ophthalmic Formulation in Patients With Allergic Conjunctivitis Using the Ora Conjunctival Allergen Challenge Model (Ora-CAC™☆) (NCT01743027)
    McLaurin, Eugene
    Narvekar, Abhijit
    Gomes, Paul J.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [16] Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials
    Bays, Harold E.
    Banach, Maciej
    Catapano, Alberico L.
    Duell, P. Barton
    Gotto, Antonio M., Jr.
    Laufs, Ulrich
    Leiter, Lawrence A.
    Mancini, G. B. John
    Ray, Kausik K.
    Bloedon, LeAnne T.
    Sasiela, William J.
    Ye, Zhan
    Ballantyne, Christie M.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2020, 14 (05) : 649 - +
  • [17] Bepotastine Besilate Ophthalmic Solution 1.5% for Up to 8 Hours Following Dosing Reduces Total Non-Ocular Symptoms, Rhinorrhea, and Tearing in a Multi-Site Clinical Model of Allergic Conjunctivitis
    Macejko, T. T.
    Meier, E. J.
    Bergmann, M. T.
    McLaurin, E. B.
    Kurata, F. K.
    Gomes, P. J.
    Williams, J. I.
    Gow, J. A.
    McNamara, T. R.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (02) : S57 - S57
  • [18] Efficacy of Dichlorphenamide in Primary Periodic Paralysis: Pooled-Data Analysis of Two Phase 3 Clinical Trials
    Shieh, Perry
    Cohen, Fredric
    Barohn, Richard
    Griggs, Robert
    NEUROLOGY, 2018, 90
  • [19] A comparison of the relative clinical efficacy of a single dose of ketotifen fumarate 0.025% ophthalmic solution versus placebo in inhibiting the signs and symptoms of allergic rhinoconjunctivitis as induced by the conjunctival allergen challenge model
    Crampton, HJ
    CLINICAL THERAPEUTICS, 2002, 24 (11) : 1800 - 1808
  • [20] Effect of BMI on Baricitinib Efficacy: Pooled Analysis from Two Phase 3 Rheumatoid Arthritis Clinical Trials
    Zerbini, Cristiano A. F.
    Muram, David
    Arora, Vipin K.
    Alam, Jahangir
    Curtis, Jeffrey R.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
12345